Search Results - "Elaidi, R-T." :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Tumor molecular characteristics in patients (pts) with international metastatic renal cell carcinoma database consortium (IMDC) good (G) and intermediate/poor (I/P) risk

Tumor molecular characteristics in patients (pts) with international metastatic renal cell carcinoma database consortium (IMDC) good (G) and intermediate/poor (I/P) risk

by Beuselinck, B., Verbiest, A., Couchy, G., Job, S., de Reyniès, A., Caruso, S., Verkarre, V., Rioux-Leclercq, N., Schöffski, P., Vano, Y., Elaidi, R.-T., Lerut, E., Albersen, M., Oudard, S., Zucman-Rossi, J.
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

Neuroendocrine carcinoma of the urinary bladder: A large analysis of the French GETUG consortium

Neuroendocrine carcinoma of the urinary bladder: A large analysis of the French GETUG consortium

by Sroussi, M., Lorcet, M., Tardy, M.P., Guerin, M., Estrade, F., Delva, R., Barthelemy, P., Lavaud, P., Neuzillet, Y., Penel, N., Houede, N., Pouessel, D., Mussat, E., Gross Goupil, M., Gauthier, H., Gobert, A., Huillard, O., Allory, Y., Elaidi, R.-T., Oudard, S.
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration

Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration

by BAMIAS, A, TZANNIS, K, STRAVODIMOS, K, CHRISOFOS, M, FOUNTZILAS, G, ELAIDI, R.-T, DIMOPOULOS, M. A, BAMIA, C, BEUSELINCK, B, OUDARD, S, ESCUDIER, B, DIOSYNOPOULOS, D, PAPAZISIS, K, LANG, H, WOLTER, P, DE GUILLEBON, E
Published in British journal of cancer (23.07.2013)

Get full text

Journal Article

EP222 Indocyanine green for sentinel lymph node detection in early breast cancer: prospective evaluation of detection rate and toxicity

EP222 Indocyanine green for sentinel lymph node detection in early breast cancer: prospective evaluation of detection rate and toxicity

by Ngô, C, Sharifzadehgan, S, Lecurieux-Lafayette, C, Belhouari, H, Rousseau, D, Bonsang-Kitzis, H, Crouillebois, L, Oudard, S, Lécuru, F, Elaidi, R-T
Published in International journal of gynecological cancer (01.11.2019)

Get full text

Journal Article

1150P Progression of advanced non-small cell lung cancer after durable clinical benefit on anti-PD-1/PD-L1 monotherapy: Prolonged post-progression survival and interest of tumor growth rate

1150P Progression of advanced non-small cell lung cancer after durable clinical benefit on anti-PD-1/PD-L1 monotherapy: Prolonged post-progression survival and interest of tumor growth rate

by Pourmir, I., Elaidi, R-T., Maaradji, Z., Gazeau, B., Gibault, L., Ung, M., Fabre-Guillevin, E.
Published in Annals of oncology (01.09.2022)

Get full text

Journal Article

634P Prognostic value of the modeled PSA kinetic parameter (KELIM) in prostate cancer patients with rising PSA after primary local therapy treated in a prospective phase III trial with ADT +/- docetaxel

634P Prognostic value of the modeled PSA kinetic parameter (KELIM) in prostate cancer patients with rising PSA after primary local therapy treated in a prospective phase III trial with ADT +/- docetaxel

by Carrot, A., Elaidi, R-T., Colomban, O., Maillet, D., Tod, M., You, B., Oudard, S.
Published in Annals of oncology (01.09.2021)

Get full text

Journal Article

Nivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC)

Nivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC)

by Hans, S., Simonaggio, A., Hamidatou, K., Fournier, L., Thibault, C., Elaidi, R.-T., Oudard, S., Vano, Y.
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

960PNivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC)

960PNivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC)

by Hans, S, Simonaggio, A, Hamidatou, K, Fournier, L, Thibault, C, Elaidi, R-T, Oudard, S, Vano, Y
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

960P - Nivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC)

960P - Nivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC)

by Hans, S., Simonaggio, A., Hamidatou, K., Fournier, L., Thibault, C., Elaidi, R.-T., Oudard, S., Vano, Y.
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

673P Cabozantinib-nivolumab (CN) vs. nivolumab-cabozantinib (NC) in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) following one prior VEGFR tyrosine kinase inhibitor (TKI): The CABIR multicentric matching-adjusted study

673P Cabozantinib-nivolumab (CN) vs. nivolumab-cabozantinib (NC) in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) following one prior VEGFR tyrosine kinase inhibitor (TKI): The CABIR multicentric matching-adjusted study

by Vano, Y., Phan, L., Gravis, G., Korakis, I., Schlürmann, F., Maillet, D., Bennamoun, M., Houede, N., Topart, D., Borchiellini, D., Barthelemy, P., Ratta, R., Ryckewaert, T., Hasbini, A., Hans, S., Emambux, S., Cournier, S., Braychenko, E., Elaidi, R-T., Oudard, S.M.
Published in Annals of oncology (01.09.2021)

Get full text

Journal Article

1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial

1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial

by Meylan, M., Sun, C-M., Elaidi, R-T., Moreira, M., Bougouin, A., Verkarre, V., Bennamoun, M., Chevreau, C.M., Borchiellini, D., Barthelemy, P., Pannier, D., Maillet, D., Gross Goupil, M., Tournigand, C., Braychenko, E., Phan, L., Oudard, S., Fridman, W-H., Sautes-Fridman, C., Vano, Y-A.
Published in Annals of oncology (01.09.2022)

Get full text

Journal Article

686P Angiogenesis related blood biomarkers of response to checkpoint inhibitors (IO) and VEGFR-TKI in metastatic renal cell carcinoma (mRCC): Results from the BIONIKK prospective trial

686P Angiogenesis related blood biomarkers of response to checkpoint inhibitors (IO) and VEGFR-TKI in metastatic renal cell carcinoma (mRCC): Results from the BIONIKK prospective trial

by Mauge, L., Galy-Fauroux, I., Elaidi, R-T., Ben Dhia, L., Bertil, S., Bennamoun, M., Chevreau, C.M., Borchiellini, D., Pannier, D., Maillet, D., Gross-Goupil, M., Tournigand, C., Laguerre, B., Barthelemy, P., Joly, F., Gravis, G., Zucman-Rossi, J., Oudard, S.M., Vano, Y., Helley, D.
Published in Annals of oncology (01.09.2021)

Get full text

Journal Article

NEMIO: A randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma

NEMIO: A randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma

by Thibault, C., Audenet, F., Borchiellini, D., Huillard, O., Barthelemy, P., Pouessel, D., Flechon, A., Blons, H., Sautès-Fridman, C., Sun, C.-M., Verkarre, V., Pallet, N., Mejean, A., Rouabah, M., Helali, I., Elaidi, R.-T., Oudard, S.
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

987TiP - NEMIO: A randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma

987TiP - NEMIO: A randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma

by Thibault, C., Audenet, F., Borchiellini, D., Huillard, O., Barthelemy, P., Pouessel, D., Flechon, A., Blons, H., Sautès-Fridman, C., Sun, C.-M., Verkarre, V., Pallet, N., Mejean, A., Rouabah, M., Helali, I., Elaidi, R.-T., Oudard, S.
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

987TiPNEMIO: A randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma

987TiPNEMIO: A randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma

by Thibault, C, Audenet, F, Borchiellini, D, Huillard, O, Barthelemy, P, Pouessel, D, Flechon, A, Blons, H, Sautès-Fridman, C, Sun, C-M, Verkarre, V, Pallet, N, Mejean, A, Rouabah, M, Helali, I, Elaidi, R-T, Oudard, S
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

869PDTumor molecular characteristics in patients (pts) with international metastatic renal cell carcinoma database consortium (IMDC) good (G) and intermediate/poor (I/P) risk

869PDTumor molecular characteristics in patients (pts) with international metastatic renal cell carcinoma database consortium (IMDC) good (G) and intermediate/poor (I/P) risk

by Beuselinck, B, Verbiest, A, Couchy, G, Job, S, de Reyniès, A, Caruso, S, Verkarre, V, Rioux-Leclercq, N, Schöffski, P, Vano, Y, Elaidi, R-T, Lerut, E, Albersen, M, Oudard, S, Zucman-Rossi, J
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

903PNeuroendocrine carcinoma of the urinary bladder: A large analysis of the French GETUG consortium

903PNeuroendocrine carcinoma of the urinary bladder: A large analysis of the French GETUG consortium

by Sroussi, M, Lorcet, M, Tardy, M P, Guerin, M, Estrade, F, Delva, R, Barthelemy, P, Lavaud, P, Neuzillet, Y, Penel, N, Houede, N, Pouessel, D, Mussat, E, Gross Goupil, M, Gauthier, H, Gobert, A, Huillard, O, Allory, Y, Elaidi, R-T, Oudard, S
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

INDOCYANINE GREEN FOR SENTINEL LYMPH NODE DETECTION IN EARLY BREAST CANCER: PROSPECTIVE EVALUATION OF DETECTION RATE AND TOXICITY: EP222

INDOCYANINE GREEN FOR SENTINEL LYMPH NODE DETECTION IN EARLY BREAST CANCER: PROSPECTIVE EVALUATION OF DETECTION RATE AND TOXICITY: EP222

by Ngô, C, Sharifzadehgan, S, Lecurieux-Lafayette, C, Belhouari, H, Rousseau, D, Bonsang-Kitzis, H, Crouillebois, L, Oudard, S, Lécuru, F, Elaidi, R-T
Published in International journal of gynecological cancer (01.11.2019)

Get full text

Journal Article